Clearside Biomedical, Inc., a private ophthalmic device and pharmaceutical company based in Alpharetta, Georgia, USA, have announced receipt of a $7.9M investment and a partnership with Santen Pharmaceutical Co., Ltd. The Japanese partner, head-quartered in Osaka, Japan is additionally understood to have entered research collaboration agreements with Clearside for the development of posterior ocular drug delivery technologies. Established in January 2012, Clearside focuses on targeted drug delivery through a proprietary microinjection platform which allows compartmentalization of an API within a specific area of the eye. The Japanese partner now joins Mountain Group Capital, Hatteras Venture Partners, Georgia Research Alliance Venture Fund and the Kenan Flagler Business School Private Equity Fund in the new investment.
Clearside Biomedical receives $8M boost to develop ocular microneedle technology
- by swdadmin